Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VET3-TGI Alone and With Atezolizumab in Advanced Solid Tumors
NCT06444815Phase 1Recruiting
- Sponsor
- KaliVir Immunotherapeutics
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of VET3-TGI in solid tumor (4 arms), sponsored by KaliVir Immunotherapeutics. Primary endpoints: Incidence of adverse events at 108 months, Incidence of dose limiting toxicities at 4 weeks and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
VET3-TGI
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06444815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444815.